Gene · 81
Papers2,438
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,438
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Extracellular vesicles derived from Schwann cells to enhance bone and dental tissue regeneration: a literature review. | J Nanobiotechnology | 2025 | 40646600 | PubTator, text mining | PubMed |
| Clinical Application of Genetic Testing in Nephrology. | Indian J Nephrol | 2025 | 40352897 | PubTator, text mining | PubMed |
| The mechanism of nesprin-2 accumulation at the nucleus front during confined cell migration. | Biophys J | 2025 | 40340251 | PubTator, text mining | PubMed |
| Editorial: Case reports in nephrology. | Front Nephrol | 2025 | 40260144 | PubTator, text mining | PubMed |
| Integrated bioinformatic analysis of immune infiltration and disulfidptosis related gene subgroups in type A aortic dissection. | Sci Rep | 2025 | 40258895 | PubTator, text mining | PubMed |
| Testicular stage- and cell-specific expression of F-actin-binding proteins†. | Biol Reprod | 2025 | 40207874 | PubTator, text mining | PubMed |
| Comprehensive Proteomics and Machine Learning Analysis to Distinguish Follicular Adenoma and Follicular Thyroid Carcinoma from Indeterminate Thyroid Nodules. | Endocrinol Metab (Seoul) | 2025 | 40205804 | PubTator, text mining | PubMed |
| Active microtubule-actin cross-talk mediated by a nesprin-2G-kinesin complex. | Sci Adv | 2025 | 39982998 | PubTator, text mining | PubMed |
| Establishment of a prognostic signature and immune infiltration characteristics for uterine corpus endometrial carcinoma based on a disulfidptosis/ferroptosis-associated signature. | Front Immunol | 2025 | 39931061 | PubTator, text mining | PubMed |
| Structural and functional insights into α-actinin isoforms and their implications in cardiovascular disease. | J Gen Physiol | 2025 | 39918740 | PubTator, text mining | PubMed |
| Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4. | Discov Oncol | 2025 | 39907925 | PubTator, text mining | PubMed |
| Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer. | Ann Med | 2025 | 39873429 | PubTator, text mining | PubMed |
| DANCR knockdown alleviates neuroinflammation and functional recovery after spinal cord injury via regulating the ACTN4 / STAT3 axis. | Arch Biochem Biophys | 2025 | 39798643 | PubTator, text mining | PubMed |
| High MICAL-L2 promotes cancer progression and drug resistance in renal clear cell carcinoma cells through stabilization of ACTN4 following vimentin expression. | Biochim Biophys Acta Mol Basis Dis | 2025 | 39689763 | PubTator, text mining | PubMed |
| METTL3-Dependent YTHDF2 Mediates TSC1 Expression to Regulate Alveolar Epithelial Mesenchymal Transition and Promote Idiopathic Pulmonary Fibrosis. | J Cell Physiol | 2025 | 39606797 | PubTator, text mining | PubMed |
| Splicing dysregulation in glioblastoma alters the function of cell migration-related genes. | Glia | 2025 | 39448549 | PubTator, text mining | PubMed |
| Nuclear α-actinin-4 regulates breast cancer invasiveness and EMT. | Cytoskeleton (Hoboken) | 2025 | 39143850 | PubTator, text mining | PubMed |
| Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions. | Physiol Rev | 2025 | 39115424 | PubTator, text mining | PubMed |
| A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma. | Cancer Biomark | 2025 | 38517776 | PubTator, text mining | PubMed |
| Matrix-associated extracellular vesicles modulate smooth muscle cell adhesion and directionality by presenting collagen VI. | bioRxiv | 2025 | 37645762 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81/papers?page=4